- Home
- AMIX vs GLTO Comparison
AMIX vs GLTO Comparison
Compare AMIX & GLTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMIX
- GLTO
- Stock Information
- Founded
- AMIX 2014
- GLTO 2011
- Country
- AMIX United States
- GLTO Denmark
- Employees
- AMIX N/A
- GLTO N/A
- Industry
- AMIX
- GLTO Biotechnology: Pharmaceutical Preparations
- Sector
- AMIX
- GLTO Health Care
- Exchange
- AMIX NYSE
- GLTO Nasdaq
- Market Cap
- AMIX 4.4M
- GLTO 3.5M
- IPO Year
- AMIX N/A
- GLTO 2020
- Fundamental
- Price
- AMIX $1.70
- GLTO $2.84
- Analyst Decision
- AMIX Strong Buy
- GLTO Buy
- Analyst Count
- AMIX 1
- GLTO 1
- Target Price
- AMIX $5.00
- GLTO $10.00
- AVG Volume (30 Days)
- AMIX 152.4K
- GLTO 30.0K
- Earning Date
- AMIX 05-30-2025
- GLTO 05-20-2025
- Dividend Yield
- AMIX N/A
- GLTO N/A
- EPS Growth
- AMIX N/A
- GLTO N/A
- EPS
- AMIX N/A
- GLTO N/A
- Revenue
- AMIX N/A
- GLTO N/A
- Revenue This Year
- AMIX N/A
- GLTO N/A
- Revenue Next Year
- AMIX N/A
- GLTO N/A
- P/E Ratio
- AMIX N/A
- GLTO N/A
- Revenue Growth
- AMIX N/A
- GLTO N/A
- 52 Week Low
- AMIX $1.52
- GLTO $2.01
- 52 Week High
- AMIX $75.80
- GLTO $18.00
- Technical
- Relative Strength Index (RSI)
- AMIX 39.78
- GLTO 47.18
- Support Level
- AMIX $2.10
- GLTO $2.70
- Resistance Level
- AMIX $2.82
- GLTO $3.11
- Average True Range (ATR)
- AMIX 0.21
- GLTO 0.23
- MACD
- AMIX -0.02
- GLTO 0.08
- Stochastic Oscillator
- AMIX 1.75
- GLTO 55.49
About AMIX AUTONOMIX MEDICAL INC
Autonomix Medical Inc is a development-stage medical device development company focused on advancing innovative technologies for sensing and treating disorders relating to the nervous system. Its first-in-class technology platform includes a catheter-based microchip-enabled array that can detect and differentiate neural signals with a high degree of sensitivity as demonstrated in animal studies.
About GLTO Galecto Inc.
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of cancer and liver diseases. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.